Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 22Neoplasms 16Leukemia, Myeloid, Acute 10Ovarian Neoplasms 8Neoplasm Metastasis 7Lung Neoplasms 7Lymphoma 6Hematologic Neoplasms 6Colorectal Neoplasms 6Prostatic Neoplasms 5Multiple Myeloma 5Glioblastoma 5Stomach Neoplasms 4Leukemia 4Fatigue 4Carcinoma, Non-Small-Cell Lung 4Vulvar Neoplasms 3Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Pancreatic Neoplasms 3Pain 3Myelodysplastic Syndromes 3Motor Activity 3Melanoma 3Fallopian Tube Neoplasms 3Depression 3Anxiety Disorders 3Vaginal Neoplasms 2

Interventions

tremelimumab 1pembrolizumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Watchful Waiting 1Radiotherapy 1Palliative Care 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Muscle-invasive Bladder Cancer × Palliative Care × Clear all
NCT06686381 2025-02-05

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

American University of Beirut Medical Center

Phase 2 Not yet recruiting
80 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡